News
FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the ...
Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...
Moderna (NasdaqGS:MRNA) experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong ...
1h
Zacks Investment Research on MSNModerna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to KnowIn the latest trading session, Moderna (MRNA) closed at $27.19, marking a -0.75% move from the previous day. This change lagged the S&P 500's 0.74% gain on the day. On the other hand, the Dow ...
Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...
Novavax faces a setback as the FDA requests an additional trial for COVID-19 vaccine approval. Read more here.
BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...
Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...
Novavax's COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company ...
(Reuters) -Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after ...
South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...
SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results